ArticleEuropean journal of immunology2015
Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.
Article in European journal of immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 87 citations in OpenAlex.
- Mast cell proteases and their significance in physiology, pathology, and therapeutic approaches.Pharmacological reviews · 2026Review
- Constitutively high levels of endogenous soluble ST2 inhibit food allergic responses in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Interleukin-33 at the intersection of inflammation and repair.Frontiers in allergy · 2026Review
- Low-density lipoprotein cholesterol mediates the causal association between systemic lupus erythematosus and asthma: a mediation mendelian randomization study.BMC rheumatology · 2025Article
- Article
- Article
- Endothelial cell dynamics in sepsis-induced acute lung injury and acute respiratory distress syndrome: pathogenesis and therapeutic implications.Cell communication and signaling : CCS · 2024Review
- HbA1c levels and circulating inflammatory proteins at onset of type 1 diabetes in children and adolescents.Journal of diabetes and metabolic disorders · 2022Article
- Human Lung Mast Cells: Therapeutic Implications in Asthma.International journal of molecular sciences · 2022Review
- Soluble ST2 as a Potential Biomarker for Abdominal Aortic Aneurysms-A Single-Center Retrospective Cohort Study.International journal of molecular sciences · 2022Article
- An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease.Nature aging · 2022Article
- Differences in Inflammatory Cytokine Profile in Obesity-Associated Asthma: Effects of Weight Loss.Journal of clinical medicine · 2022Article
- Unravelling the therapeutic potential of IL-33 for atrophic AMD.Eye (London, England) · 2022Review
- Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response.Frontiers in immunology · 2022Review
- Interleukin-33: Metabolic checkpoints, metabolic processes, and epigenetic regulation in immune cells.Frontiers in immunology · 2022Review
- Sex and age differences in sST2 in cardiovascular disease.Frontiers in cardiovascular medicine · 2022Article
- Review
- Soluble ST2 as a Potential Biomarker in Pericardial Fluid of Coronary Artery Patients.Brazilian journal of cardiovascular surgery · 2021Article
- Cytokine signaling convergence regulates the microglial state transition in Alzheimer's disease.Cellular and molecular life sciences : CMLS · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
IL-33 released from damaged cells plays a central role in allergic inflammation by acting through its membrane-bound receptor, ST2 receptor (ST2L). IL-33 activity can be neutralized by the soluble spliced variant of ST2 (sST2) that has been associated with allergic inflammation but its source is not well defined. We investigated whether mast cells (MCs) are a significant source of sST2 following activation through FcεRI or ST2. We find that antigen and IL-33 induce substantial production and release of sST2 from human and mouse MCs in culture and do so synergistically when added together or in combination with stem cell factor. Moreover, increases in circulating sST2 during anaphylaxis in mice were dependent on the presence of MCs. Human MCs activated via FcεRI failed to generate IL-33 and IL-33 produced by mouse bone marrow-derived MCs was retained within the cells. Therefore, FcεRI-mediated sST2 production is independent of MC-derived IL-33 acting in an autocrine manner. These results are consistent with the conclusion that both mouse and human MCs when activated are a significant inducible source of sST2 but not IL-33 and thus have the ability to modulate the biologic impact of IL-33 produced locally by other cell types during allergic inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.